Choroidal thickness changes in non-treated acute and ranibizumab-treated chronic central serous chorioretinopathy

Abstract

To evaluate the changes in subfoveal retinal, and choroidal thicknesses (CT) in the non-treated acute and the ranibizumab-treated chronic central serous chorioretinopathy (CSCR) patients.This retrospective study included 32 eyes of 32 consecutive patients with CSCR. There were 12 patients who presented with a spontaneous resolution of CSCR (Group 1) and 20 patients who were treated with ranibizumab for persistent subretinal fluid (SRF) (Group 2). Optical coherence tomography (OCT) imaging of subfoveal retinal thickness and enhanced depth imaging OCT of CT at subfoveal; at nasal and temporal 500 μm (T500); at nasal and temporal 1500 μm (T1500) were analyzed. The Student t test and multivariate analysis were used to compare variables within and between groups, respectively and correlations were analyzed using Pearson correlation coefficient. A P value of P < .05 was accepted as significant.The mean patient age was 38.94 ± 8.41 years (range, 20–53 years). Female/male ratio was 4/28. The mean duration of follow-up was 21.6 ± 8.2 months in the chronic CSCR group. Visual acuity improved and central foveal thickness (FT) decreased significantly in both groups. CT decreased significantly only at nasal 1500 μm (N1500) in the acute group and at all measured points in the chronic group compared with baseline, except at T500 (P = .07). No significant difference in central FT was detected between the 2 groups. Compared with the acute group, baseline subfoveal CT was significantly higher in chronic patients. There was a significant difference between the groups in baseline and final CT at T500. No significant difference was found at T1500. At nasal 500 μm and N1500, the difference between the groups was significant only for final CT values.Chronic CSCR was associated with higher baseline CT values in the subfoveal region and at T500. CT significantly decreased at most of the measured points in ranibizumab-treated chronic CSCR patients, whereas it significantly decreased only at 1 point in spontaneously resolved acute CSCR patients.

Effect of photodynamic therapy on choroid of the medial area from optic disc in patients with central serous chorioretinopathy

“…The efficacy of PDT for chronic CSC has been reported previously, however [ 2 , 3 , 11 ], and it is ethically challenging to follow up on chronic CSC without treatment. In addition, since the current results are relatively large compared to choroidal changes during spontaneous remission in acute CSC [ 35 , 36 ], we believe that the choroidal changes observed in this study were related to PDT.…”

Intravitreal anti-vascular endothelial growth factor for the treatment of chronic central serous retinopathy: a meta-analysis of the literature

“…A total of 20 studies were included in this systematic review (n=339 eyes) 3–5 16 20 22–36. Twelve were prospective studies (n=165),3–5 22–25 29–32 34 seven were retrospective studies (n=173)16 26–28 33 35 36 and one was a case report (n=1) 20.…”

RPE/Bruch’s Membrane Complex Micro-Rips in Central Serous Chorioretinopathy

“…This hypothesis was confirmed by recent studies, which found evidence of hyperpermeability from the choriocapillaris on Indocyanine green (ICG) angiography. If there is sufficient hydrostatic pressure from the choroidal vasculature causing leakage from RPE and serous retinal detachment [16]. SD-OCT studies of the RPE in CSC have shown RPE defects in the location of a fluorescein leakage in some patients [17].…”